News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
14,430 Results
Type
Article (2954)
Company Profile (2)
Press Release (11474)
Section
Business (5074)
Career Advice (41)
Deals (782)
Drug Delivery (17)
Drug Development (3097)
Employer Resources (9)
FDA (475)
Job Trends (770)
News (8973)
Policy (1202)
Tag
Academia (73)
Adcomms (4)
Allergies (1)
Alliances (1519)
ALS (1)
Alzheimer's disease (17)
Antibody-drug conjugate (ADC) (29)
Approvals (469)
Artificial intelligence (6)
Bankruptcy (7)
Best Places to Work (545)
BIOSECURE Act (2)
Biosimilars (4)
Bladder cancer (6)
Brain cancer (1)
Breast cancer (35)
Cancer (150)
Cardiovascular disease (13)
Career advice (43)
Career pathing (3)
CAR-T (1)
Cell therapy (9)
Cervical cancer (1)
Clinical research (2295)
Collaboration (14)
Compensation (3)
Complete response letters (1)
COVID-19 (443)
CRISPR (3)
C-suite (13)
Data (39)
Decentralized trials (1)
Denatured (1)
Diabetes (7)
Diagnostics (123)
Diversity (1)
Diversity, equity & inclusion (1)
Drug discovery (7)
Drug pricing (30)
Earnings (1281)
Editorial (5)
Employer branding (5)
Employer resources (10)
Events (1487)
Executive appointments (28)
FDA (486)
Funding (9)
Gene editing (4)
Generative AI (1)
Gene therapy (6)
GLP-1 (91)
Government (329)
Healthcare (311)
IgA nephropathy (1)
Immunology and inflammation (6)
Infectious disease (452)
Inflammatory bowel disease (3)
Inflation Reduction Act (4)
Influenza (3)
Intellectual property (3)
Interviews (2)
IPO (249)
IRA (21)
Job creations (257)
Job search strategy (40)
Kidney cancer (2)
Labor market (1)
Layoffs (32)
Leadership (2)
Legal (262)
Liver cancer (11)
Lung cancer (52)
Lymphoma (9)
Management (3)
Manufacturing (12)
Medical device (52)
Medtech (52)
Mergers & acquisitions (531)
Metabolic disorders (27)
Neurodegenerative disease (1)
Neuroscience (21)
NextGen: Class of 2025 (127)
Non-profit (68)
Northern California (42)
Obesity (19)
Opinion (31)
Ovarian cancer (2)
Pain (3)
Pancreatic cancer (10)
Patents (11)
Patient recruitment (1)
People (1984)
Pharmaceutical (2)
Pharmacy benefit managers (1)
Phase I (666)
Phase II (857)
Phase III (1261)
Pipeline (25)
Podcasts (9)
Policy (27)
Postmarket research (127)
Preclinical (183)
Press Release (3)
Prostate cancer (5)
Psychedelics (1)
Radiopharmaceuticals (23)
Rare diseases (11)
Real estate (132)
Recruiting (5)
Regulatory (729)
Research institute (72)
Resumes & cover letters (1)
RSV (4)
Schizophrenia (2)
Series A (5)
Sickle cell disease (1)
Southern California (22)
Special edition (2)
Startups (113)
Stomach cancer (3)
Supply chain (1)
The Weekly (8)
United States (323)
Vaccines (90)
Webinars (1)
Weight loss (20)
Women's health (1)
Date
Today (3)
Last 7 days (12)
Last 30 days (62)
Last 365 days (880)
2025 (135)
2024 (903)
2023 (858)
2022 (1719)
2021 (1703)
2020 (1505)
2019 (888)
2018 (622)
2017 (757)
2016 (797)
2015 (925)
2014 (632)
2013 (428)
2012 (421)
2011 (362)
2010 (326)
Location
Africa (52)
Asia (1199)
Australia (156)
California (75)
Canada (21)
China (19)
Colorado (1)
Connecticut (8)
Delaware (32)
Europe (3690)
Florida (22)
Idaho (1)
Illinois (8)
Japan (13)
Maryland (12)
Massachusetts (68)
Minnesota (1)
New Hampshire (1)
New Jersey (46)
New York (16)
North Carolina (10)
Northern California (42)
Ohio (15)
Oregon (1)
Pennsylvania (6)
South America (54)
Southern California (22)
Texas (4)
Virginia (1)
Washington D.C. (6)
Washington State (3)
14,430 Results for "astrazeneca".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Stomach cancer
AstraZeneca Builds Stomach Cancer Case for Imfinzi With Strong Phase III Data
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The PD-L1 blocker brought in over $4.7 billion in sales last year.
March 7, 2025
·
2 min read
·
Tristan Manalac
Earnings
AstraZeneca Axes Two Alexion Assets as Q4 Earnings Exceed Expectations
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” deal for the pharma.
February 6, 2025
·
3 min read
·
Tristan Manalac
Cancer
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments in terms of progression-free survival, according to AstraZeneca.
February 26, 2025
·
1 min read
·
Dan Samorodnitsky
Mergers & acquisitions
AstraZeneca Buys FibroGen’s China Unit for $160M as Probes Continue
A year ago, AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to retain its relationship with the biotech’s China operations.
February 20, 2025
·
2 min read
·
Tristan Manalac
Prostate cancer
AstraZeneca’s Truqap Redeems Itself with Phase III Prostate Cancer Win
Truqap’s positive clinical data comes after it failed a late-stage study in metastatic triple-negative breast cancer. It helps AstraZeneca position itself as a top player in the prostate cancer space, alongside its Big Pharma colleagues.
November 26, 2024
·
2 min read
·
Tristan Manalac
China
AstraZeneca’s Stock Price Takes a Hit as China Chief Investigated for Insurance Fraud
BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” to AstraZeneca, but contends that the share selloff is “overdone” and likely a knee-jerk reaction by investors.
November 6, 2024
·
2 min read
·
Tristan Manalac
Podcast
AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More
A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an investigation into China exec, the Huntington’s pipeline builds momentum and layoffs continue with Sana Biotechnology and 23andMe.
November 13, 2024
·
1 min read
·
Heather McKenzie
Cancer
AstraZeneca/Daiichi Sankyo, BioNTech, Merus to Present Promising Cancer Therapies at ESMO Asia 2024
At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus will reveal promising mid-stage data for their respective cancer candidates.
December 2, 2024
·
4 min read
·
Tristan Manalac
Press Releases
AstraZeneca’s Full Year and Q4 2024 results
February 6, 2025
·
10 min read
Obesity
AstraZeneca Bolsters Obesity Pipeline With Promising Early Data for Candidates
While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb studies and creates a “foothold” for AstraZeneca in the weight loss space.
November 5, 2024
·
3 min read
·
Tristan Manalac
1 of 1,443
Next
